» Articles » PMID: 38108075

Research Progress on Ferroptosis in Gliomas (Review)

Overview
Journal Oncol Lett
Specialty Oncology
Date 2023 Dec 18
PMID 38108075
Authors
Affiliations
Soon will be listed here.
Abstract

Glioma is the most prevalent type of brain tumor characterized by a poor 5-year survival rate and a high mortality rate. Malignant gliomas are commonly treated by surgery, chemotherapy and radiotherapy. However, due to toxicity and resistance to chemoradiotherapy, these treatments can be ineffective. Anxiety and depression are highly prevalent in patients with glioma, adversely affecting disease prognosis and posing societal concerns. Ferroptosis is a type of non-apoptotic, iron-dependent cell death characterized by the accumulation of lethal reactive oxygen species produced by iron metabolism, and it serves a key role in numerous diseases. Regulation of iron phagocytosis may serve as a therapeutic strategy for the development of novel glioma treatments. The present review discusses the mechanisms underlying the occurrence and regulation of ferroptosis, its role in the genesis and evolution of gliomas, and its association with glioma-related anxiety and depression. By exploring potential targets for glioma treatment, the present review provides a theoretical basis for the development of novel therapeutic strategies against glioma.

Citing Articles

Multifaceted bioinformatic analysis of m6A-related ferroptosis and its link with gene signatures and tumour-infiltrating immune cells in gliomas.

Yang Y, Hao L, Guiyang L, Haozhe P J Cell Mol Med. 2024; 28(17):e70060.

PMID: 39248438 PMC: 11382363. DOI: 10.1111/jcmm.70060.


The interplay between metal ions and immune cells in glioma: pathways to immune escape.

Li J, Mao Y, Chen S, Ye R, Fei Y, Li Y Discov Oncol. 2024; 15(1):348.

PMID: 39134820 PMC: 11319581. DOI: 10.1007/s12672-024-01229-0.


Diethyldithiocarbamate-ferrous oxide nanoparticles inhibit human and mouse glioblastoma stemness: aldehyde dehydrogenase 1A1 suppression and ferroptosis induction.

Abu-Serie M, Osuka S, Heikal L, Teleb M, Barakat A, Dudeja V Front Pharmacol. 2024; 15:1363511.

PMID: 38720782 PMC: 11076782. DOI: 10.3389/fphar.2024.1363511.

References
1.
Doll S, Porto Freitas F, Shah R, Aldrovandi M, Costa Da Silva M, Ingold I . FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019; 575(7784):693-698. DOI: 10.1038/s41586-019-1707-0. View

2.
Gathinji M, McGirt M, Attenello F, Chaichana K, Than K, Olivi A . Association of preoperative depression and survival after resection of malignant brain astrocytoma. Surg Neurol. 2008; 71(3):299-303, discussion 303. DOI: 10.1016/j.surneu.2008.07.016. View

3.
Dixon S, Lemberg K, Lamprecht M, Skouta R, Zaitsev E, Gleason C . Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149(5):1060-72. PMC: 3367386. DOI: 10.1016/j.cell.2012.03.042. View

4.
Wong B, Tsatsanis A, Lim L, Adlard P, Bush A, Duce J . β-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS One. 2014; 9(12):e114174. PMC: 4252103. DOI: 10.1371/journal.pone.0114174. View

5.
Conrad M, Lorenz S, Proneth B . Targeting Ferroptosis: New Hope for As-Yet-Incurable Diseases. Trends Mol Med. 2020; 27(2):113-122. DOI: 10.1016/j.molmed.2020.08.010. View